{"id":70731,"date":"2026-06-26T04:33:47","date_gmt":"2026-06-26T04:33:47","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/70731\/"},"modified":"2026-06-26T04:33:47","modified_gmt":"2026-06-26T04:33:47","slug":"astrazeneca-publish-1st-quarter-results-april-29-2026","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/70731\/","title":{"rendered":"AstraZeneca Publish 1st Quarter Results April 29, 2026"},"content":{"rendered":"<p class=\"has-large-font-size wp-block-paragraph\">AstraZeneca results: Q1 2026<\/p>\n<p class=\"wp-block-paragraph\">Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition<\/p>\n<p class=\"wp-block-paragraph\">Revenue and EPS summary<\/p>\n<p>Q1 2026% Change$mActualCER1\u2013 Product Sales14,386127\u2013 Alliance Revenue8252926Product Revenue15,211138Collaboration Revenue774\u2013Total Revenue15,288138Reported EPS ($)1.9968Core2\u00a0EPS ($)2.5845<\/p>\n<p class=\"wp-block-paragraph\">Key performance elements for Q1 2026<\/p>\n<p class=\"wp-block-paragraph\">(Growth numbers at constant exchange rates)<\/p>\n<p class=\"wp-block-paragraph\">*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Total Revenue up 8% to $15,288m, driven by double\u2011digit growth in Oncology and Rare Disease<\/p>\n<p class=\"wp-block-paragraph\">*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Core Operating profit increased 12%<\/p>\n<p class=\"wp-block-paragraph\">*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Core EPS growth of 5%, reflecting the favourable tax rate in the prior year period<\/p>\n<p class=\"wp-block-paragraph\">*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Core Tax rate of 21%. Expectations for full year Core Tax rate are unchanged at 18-22%<\/p>\n<p class=\"wp-block-paragraph\">*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Positive readouts for four high-value Phase III programmes since Q4 2025 results, including for two NMEs: tozorakimab and efzimfotase alfa<\/p>\n<p class=\"wp-block-paragraph\">*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a014 approvals in major regions since Q4 2025 results<\/p>\n<p class=\"wp-block-paragraph\">Pascal Soriot, Chief Executive Officer, AstraZeneca, said:<\/p>\n<p class=\"wp-block-paragraph\">\u201cWe delivered strong growth in Q1 2026, with Total Revenue above $15 billion, demonstrating our consistent commercial execution. We are advancing through our catalyst\u2011rich period, with positive readouts for four high-value Phase III programmes since our last quarterly results, including first pivotal data for two key NMEs \u2013 tozorakimab in COPD and efzimfotase alfa in hypophosphatasia.<\/p>\n<p class=\"wp-block-paragraph\">We continue to invest in our commercial capabilities as we prepare for multiple launches, look forward to further readouts anticipated this year, and remain on track to achieve our ambition for 2030 and beyond.\u201d<\/p>\n<p class=\"wp-block-paragraph\"><a href=\"http:\/\/www.rns-pdf.londonstockexchange.com\/rns\/2991C_1-2026-4-28.pdf\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/www.rns-pdf.londonstockexchange.com\/rns\/2991C_1-2026-4-28.pdf<\/a><\/p>\n<p class=\"wp-block-paragraph\">Guidance<\/p>\n<p class=\"wp-block-paragraph\">AstraZeneca reconfirms Total Revenue and Core EPS guidance3\u00a0for FY 2026 at CER, based on the average foreign exchange rates through 2025.<\/p>\n<p class=\"has-text-align-center wp-block-paragraph\">Total Revenue\u00a0is expected to increase by a\u00a0mid-to\u2013high single-digit\u00a0percentage<\/p>\n<p class=\"has-text-align-center wp-block-paragraph\">Core EPS\u00a0is expected to increase by a\u00a0low double-digit\u00a0percentage<\/p>\n<p class=\"wp-block-paragraph\">The Core Tax rate is expected to be between 18-22%<\/p>\n<p class=\"wp-block-paragraph\">If foreign exchange rates for April 2026 to December 2026 were to remain at the average rates seen in March 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact (unchanged) compared to the performance at CER, and Core EPS growth would be broadly similar (unchanged) to the growth at CER.<\/p>\n","protected":false},"excerpt":{"rendered":"AstraZeneca results: Q1 2026 Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition&hellip;\n","protected":false},"author":2,"featured_media":523,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,21721,18,11966,2840,372],"class_list":["post-70731","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-azn","tag-news","tag-q1-2026","tag-results","tag-update"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116814548990353569","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/70731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=70731"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/70731\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/523"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=70731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=70731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=70731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}